去年，Integra Lifesciences Holdings Corp表现最佳的业务板块Neurosurgery实现营收827.67M美元。United States的营收贡献最高，去年达到1.20B美元。最近一个季度，截至2026-06-30，Integra Lifesciences Holdings Corp表现最佳的业务板块Neurosurgery实现营收213.26M美元。United States的营收贡献最高，达到307.10M美元。

业务

营业收入

占比

年报

年报

单季报

Neurosurgery

Wound Reconstruction and Care

Instruments

ENT

Private Label

Extremity Orthopedics

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

Neurosurgery

827.67M(50.61%)

803.82M(49.91%)

818.10M(53.07%)

794.02M(50.97%)

802.96M(52.06%)

716.34M(52.22%)

707.01M(46.59%)

Wound Reconstruction and Care

323.49M(19.78%)

350.56M(21.77%)

373.99M(24.26%)

406.69M(26.11%)

392.46M(25.44%)

293.04M(21.36%)

322.74M(21.27%)

Instruments

206.47M(12.63%)

204.18M(12.68%)

240.89M(15.63%)

225.55M(14.48%)

222.27M(14.41%)

178.49M(13.01%)

289.19M(19.06%)

ENT

166.37M(10.17%)

135.64M(8.42%)

--(--)

Private Label

111.25M(6.80%)

116.33M(7.22%)

108.59M(7.04%)

131.41M(8.44%)

124.75M(8.09%)

105.68M(7.70%)

108.53M(7.15%)

Extremity Orthopedics

--(--)

78.32M(5.71%)

90.08M(5.94%)

地区

营业收入

占比

年报

年报

单季报

United States

Asia Pacific

Europe

Rest of World

Asia/Pacific

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

United States

1.20B(73.67%)

1.19B(66.74%)

1.10B(63.45%)

1.13B(72.34%)

1.09B(70.64%)

971.98M(70.85%)

1.08B(70.99%)

Asia Pacific

189.25M(11.57%)

176.61M(9.88%)

193.10M(11.13%)

--(--)

Europe

162.67M(9.95%)

158.50M(8.87%)

165.22M(9.52%)

170.90M(10.97%)

191.33M(12.40%)

172.69M(12.59%)

197.47M(13.01%)

Rest of World

78.58M(4.81%)

82.74M(4.63%)

82.53M(4.76%)

83.48M(5.36%)

79.56M(5.16%)

70.03M(5.10%)

85.32M(5.62%)

Asia/Pacific

--(--)

176.61M(9.88%)

193.10M(11.13%)

176.48M(11.33%)

182.03M(11.80%)

157.17M(11.46%)

157.39M(10.37%)